Imatinib, a specific tyrosine kinase inhibitor that targets the BCR‐ABL, KIT and PDGFR receptors, is used to treat various cancers, including but not limited to chronic myeloid leukaemia and gastrointestinal stromal tumours.44 This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.